Some Pharmacokinetic Parameters of Oxfendazole in Sheep

Soraci, A.L., Mestorino, N. and Errecalde, J.O., 1997. Some pharmacokinetic parameters of oxfendazole in sheep. Veterinary Research Communications, 21 (4), 283-287     

Sulfadiazine pharmacokinetics in grass carp (Ctenopharyngodon idellus) receiving oral and intravenous administrations

This study aimed to examine the bioavailability (BA) and pharmacokinetic (PK) characteristics of sulfadiazine (SDZ) in grass carp (Ctenopharyngodon idellus) after oral and intravenous administrations. Blood samples were collected at predetermined time points of 0.083, 0.17, 0.5, 1, 2, 4, 8, 16, 24, 48, 72, and 96 hr (n = 6). The samples were extracted and purified by organic reagents and determined by the ultra‐performance liquid chromatography. The software named 3P97 was used to calculate relevant PK parameters. The results demonstrated that the concentration–time profile of SDZ was best described by a one‐compartmental open model with first‐order absorption after a single oral dose. The main PK parameters of the absorption rate constant (K_α), the absorption half‐life (t_{1/2 Kα}), the elimination rate constant (K_e), the elimination half‐life (t_1/2Ke), and the area under concentration–time profile (AUC_0‐∞) were 0.3 1/h, 2.29 hr, 0.039 1/h, 17.64 hr, and 855.78 mg.h/L, respectively. Following intravenous administration, the concentration–time curve fitted to a two‐compartmental open model without absorption. The primary PK parameters of the distribution rate constant (α), the elimination rate constant (β), the distribution half‐life (t_1/2α), the elimination half‐life (t_1/2β), the apparent distribution volume (V_SS), the total clearance (CL), and AUC_0‐∞ were 9.62 1/hr, 0.039 1/hr, 0.072 hr, 17.71 hr, 0.33 L/kg, 0.013 L h^?1 kg^?1, and 386.23 mg.h/L, respectively. Finally, the BA was calculated to be 22.16%. Overall, this study will provide some fundamental information on PK properties in the development of a new formulation SDZ in the future and is partially beneficial for the appropriate usage of SDZ in aquaculture.     

Pharmacokinetic comparison of six anthelmintics in sheep,goats, and cattle

This study was initiated to determine whether a comparative pharmacokinetic (PK) approach could be used to expand the pool of approved anthelmintics for minor ruminant species. Accordingly, the PK profiles of six anthelmintics (levamisole, albendazole, fenbendazole, moxidectin, doramectin, and ivermectin) in sheep, goats, and cattle were determined. The PK values determined for each anthelmintic included T_max, T_last, C_max, AUC, AUC/dose, and C_max/dose. The results of this study demonstrate that a comparative PK approach does not show commonality in the way these six anthelmintics are individually processed by these three ruminants. While some drugs demonstrated identical PK profiles between sheep and goats, none of these drugs demonstrated PK profiles in sheep and goats comparable to the PK profiles found in cattle. The results from this study suggest drug approval across these three ruminants is not a viable concept. However, the resulting PK profiles for each combination of drug and ruminant species represents a new dataset that can be used to support the US FDA Center for Veterinary Medicine's Minor Use/Minor Species indexing process for drug approvals in minor species such as sheep and goats.     

Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus)

The objectives of this study were (a) to establish a population pharmacokinetic model and (b) to investigate the clinical and physiological effects of a single bolus dose of propofol in common marmosets. In Study 1, pharmacokinetic analysis was performed in six marmosets under sevoflurane anaesthesia. 8 mg/kg of propofol was administrated at a rate of 4 mg kg^?1 min^?1. Blood samples were collected 2, 5, 15, 30, 60, 90, 120 or 180 min after starting propofol administration. Plasma concentration was measured, and population pharmacokinetic modelling was performed. A two‐compartment model was selected as the final model. The population pharmacokinetic parameters were as follows: V₁ = 1.14 L, V₂ = 77.6 L, CL₁ = 0.00182 L/min, CL₂ = 0.0461 L/min. In Study 2, clinical and physiological parameters were assessed and recorded every 2 min after 12 mg/kg of propofol was administrated at a rate of 4 mg kg^?1 min^?1. Immobilization was sustained for 5 min following propofol administration without apparent bradycardia. While combination of propofol and sevoflurane caused apnoea in Study 1, apnoea was not observed following single administration of propofol in Study 2. These data provide bases for further investigation on intravenous anaesthesia using propofol in common marmosets.     

Pharmacokinetics of detomidine and its metabolites following intravenous and intramuscular administration in horses

Reasons for performing study: Detomidine is commonly used i.v. for sedation and analgesia in horses, but the pharmacokinetics and metabolism of this drug have not been well described. Objectives: To describe the pharmacokinetics of detomidine and its metabolites, 3‐hydroxy‐detomidine (OH‐detomidine) and detomidine 3‐carboxylic acid (COOH‐detomidine), after i.v. and i.m. administration of a single dose to horses. Methods: Eight horses were used in a balanced crossover design study. In Phase 1, 4 horses received a single dose of i.v. detomidine, administered 30 μg/kg bwt and 4 a single dose i.m. 30 üg/kg bwt. In Phase 2, treatments were reversed. Plasma detomidine, OH‐detomidine and COOH‐detomidine were measured at predetermined time points using liquid chromatography‐mass spectrometry. Results: Following i.v. administration, detomidine was distributed rapidly and eliminated with a half‐life (t_1/2(el)) of approximately 30 min. Following i.m. administration, detomidine was distributed and eliminated with t_1/2(el) of approximately one hour. Following, i.v. administration, detomidine clearance had a mean, median and range of 12.41, 11.66 and 10.10–18.37 ml/min/kg bwt, respectively. Detomidine had a volume of distribution with the mean, median and range for i.v. administration of 470, 478 and 215–687 ml/kg bwt, respectively. OH‐detomidine was detected sooner than COOH‐detomidine; however, COOH‐detomidine had a much greater area under the curve. Conclusions and potential relevance: These pharmacokinetic parameters provide information necessary for determination of peak plasma concentrations and clearance of detomidine in mature horses. The results suggest that, when a longer duration of plasma concentration is warranted, the i.m. route should be considered.     

治疗多重耐药革兰氏阴性菌感染的有效抗菌药——多黏菌素

综述了多黏菌素的理化性质、抗菌活性、药动学、药效学、临床应用、残留等方面的特点和研究概况,以期为该药在兽医临床上的应用提供依据。     

磺胺—6—甲氧嘧啶在京Ⅲ鸡体内的药物代谢动力学

本文报告了磺胺—6—甲氧嘧啶(DS—36)在京Ⅲ鸡体内的药物代谢动力学(简称药动学)。用夏普PC—1500袖珍计算机,对血药浓度—时间数据进行药动学模型嵌合,并选用合适的动力学模型描述了DS—36的药动学特点。结果表明:静注DS—36后,血药经时过程符合无吸收因素二室模型。tyαβ=9.26±0.60(hr),Vd=8.40±1.60(100ml/kg·hr),Tcp(ther)=11.29±2.94(hr)。京Ⅲ鸡在单剂量胃管投服DS-36混悬液(100mg/kg)后,血药浓度变化符合有吸收因素一空模型。ka=0.513±0.0992(hr~(-1)),T_(max)=4.42+0.57(hr)、C_(max)=9.11±0.25(mg%),tyαke=9.38±0.49(hr),生物利用度F=94.47%。根据单剂量给药参数计算出多剂量给药参数,推荐的口服治疗方案为:负荷剂量Do=170mg/kg,维持剂量Do=100mg/kg,给药间隔L=12(hr)。     

静注克洛素隆在绵羊体内的药代动力学研究

应用YWG-C18色谱柱(250 mm×4.6 mm,5μm),WatersTM 486型可调波长紫外检测器(检测波长265 nm);0.01 M磷酸钾(pH=7)乙腈(3 1)为流动相;含量测定采用标准曲线法,建立了RP-HPLC法检测绵羊血浆中克洛素隆含量的方法.同时对绵羊单剂量静脉注射7 mg/kg克洛素隆的药代动力学进行了研究.血药浓度在0.005～2.0 μg/ml及2.0～50.0μg/ml范围呈良好线性关系(r=0.9941、0.9970),平均回收率93.2%,血药最低检测浓度0.005μg/ml,日内日间变异系数分别小于10%、11%.血药浓度结果经MCPKP药代动力学统计软件处理,体内药物运转符合三室开放模型,主要药物动力学参数t1/2γ=14.14 h,Kel=0.3260 h-1,AUC=153.95 mg/l@h,fc=0.055.结果表明克洛素隆静脉单次给药后体内分布较为广泛,持续作用时间长,主要通过肾脏排泄.     

恩诺沙星及其代谢产物在奶山羊的药动学及乳中药物浓度

本试验研究单剂量静脉注射、肌肉注射和乳房灌注恩诺沙星（2.5mg/kg)在健康奶山羊的药动学及乳中药物浓度。采用HPLC法测定血浆和乳中恩诺沙星及其代谢产物环丙沙星的浓度，用统计矩原理处理血浆中药物浓度－时间数据，计算非房室模型的药动学参数。静脉注射、肌肉注射和乳房灌注恩诺沙星的t1/2β分别为1.32、1．55、0．99h;AUC为1．06、3．04、2．66mghL^-1；恩诺沙星的代谢分数为35．01％、44．06％、45．73％；环丙沙星的t1/2β为1．81、2．94、2．32h。乳中的药物浓度高于同期血中药物浓度，且乳中环丙沙星浓度高于恩诺沙星浓度并维持更长的时间。